





journal homepage: www.FEBSLetters.org

Defining the structural requirements for ribose 5-phosphate-binding and intersubunit cross-talk of the malarial pyridoxal 5-phosphate synthase

Bianca Derrer^a, Volker Windeisen^b, Gabriela Guédez Rodríguez^b, Joerg Seidler^c, Martin Gengenbacher^{a,1}, Wolf D. Lehmann^c, Karsten Rippe^d, Irmgard Sinning^b, Ivo Tews^{b,*}, Barbara Kappes^{a,**}

ARTICLE INFO

Article history:
Received 12 April 2010
Revised 23 July 2010
Accepted 2 September 2010
Available online 17 September 2010

Edited by Stuart Ferguson

Keywords: Vitamin B₆ Pyridoxal 5-phosphate (PLP) synthase Malaria Pdx1/Pdx2 Protein protein interaction Ribose 5-phosphate-binding

ABSTRACT

Most organisms synthesise the B₆ vitamer pyridoxal 5-phosphate (PLP) via the glutamine amidotransferase PLP synthase, a large enzyme complex of 12 Pdx1 synthase subunits with up to 12 Pdx2 glutaminase subunits attached. Deletion analysis revealed that the C-terminus has four distinct functionalities: assembly of the Pdx1 monomers, binding of the pentose substrate (ribose 5-phosphate), formation of the reaction intermediate I₃₂₀, and finally PLP synthesis. Deletions of distinct C-terminal regions distinguish between these individual functions. PLP formation is the only function that is conferred to the enzyme by the C-terminus acting *in trans*, explaining the cooperative nature of the complex.

Structured summary:

MINT-7994448: PfPdx1 (uniprotkb:C6KT50) and PfPdx1 (uniprotkb:C6KT50) bind (MI:0407) by molecular sieving (MI:0071)

MINT-7994425, MINT-7994413, MINT-7994435: *PfPdx1* (uniprotkb:C6KT50) and *PfPdx1* (uniprotkb:C6KT50) bind (MI:0407) by cosedimentation in solution (MI:0028).

 $\hbox{@ 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All \ rights \ reserved.}$

1. Introduction

Malaria is caused by parasites of the genus *Plasmodium*. It is a disease that imposes a tremendous burden on global health putting over 2 billion people at risk and afflicting over 500 million people worldwide [1]. As current therapeutics are increasingly ineffective [2] and a clinically available vaccine is not in sight, there is an urgent need to identify and characterize new targets enabling novel chemotherapeutic strategies. The biosynthesis of vitamins is of particular interest in this respect, since the absence of these pathways in humans implies that their inhibition exclusively affects the metabolism of the parasite and not that of the human

host. *Plasmodium* is able to synthesize certain vitamins *de novo*, either completely or in parts [3,4]. Among these is vitamin B_6 [5,6].

The term vitamin B₆ collectively refers to the vitamers pyridoxal, pyridoxine, pyridoxamine and their related phosphate esters. The metabolically active forms are pyridoxal 5-phosphate (PLP) und pyridoxamine 5-phosphate (PMP). PLP has been described as nature's most versatile cofactor and is involved in more than 100 enzymatic reactions [7,8]. In the malaria parasite, PLP is synthesized through the so-called deoxyxylose 5-phosphate independent pathway, in which the proteins Pdx1 and Pdx2 form a heteromeric class I glutamine amidotransferase [5,6]. The fully assembled PLP synthase complex consists of two interacting Pdx1 hexamers plus up to 12 Pdx2 molecules attached to them [9,23]. The glutaminase subunit Pdx2 generates ammonia through the hydrolysis of glutamine - the source of the required ring nitrogen in the synthase reaction catalyzed by Pdx1 [11,12]. Ribose 5-phosphate (R5P) and glyceraldehyde 3-phosphate (G3P) are substrates of the synthase reaction catalysed by Pdx1 along with ammonia provided by Pdx2 [13].

The activity of the PLP synthase system is highly regulated [7,14–19]. Cooperativity between Pdx1 subunits is induced upon

^a University Hospital Heidelberg, Department of Infectious Diseases, Parasitology, Im Neuenheimer Feld 324, 69120 Heidelberg, Germany

^b Heidelberg University Biochemistry Center (BZH), Im Neuenheimer Feld 328, 69120 Heidelberg, Germany

^c German Cancer Research Center, Molecular Structure Analysis, Heidelberg, Germany

d German Cancer Research Center and Bioquant, Research Group Genome Organization and Function, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany

Abbreviations: PfPdx1, Pdx1 of Plasmodium falciparum; PfPdx2, Pdx2 of Plasmodium falciparum; PLP, pyridoxal 5-phosphate; IPTG, isopropyl β -p-1-thioglacatopyranoside; R5P, ribose 5-phosphate; G3P, glyceraldehyde 3-phosphate

^{*} Corresponding author. Tel.: +49 6221 544785; fax: +49 6221 544749.

^{**} Corresponding author. Tel.: +49 6221 561774; fax: +49 6221 564643.

E-mail addresses: ivo.tews@bzh.uni-heidelberg.de (I. Tews), barbara.kappes@ur-z.uni-heidelberg.de (B. Kappes).

¹ Present address: Max Planck Institute for Infection Biology, Department of Immunology, Charitéplatz 1, 10117 Berlin, Germany.

binding of the pentose substrate [18]. Moreover, Pdx2 acts as an allosteric effector of Pdx1 when its substrate glutamine is bound and then further enhances the affinity of Pdx1 for R5P [18]. Combined cross-linking and mass spectrometry data suggest an intersubunit cross-talk by interaction of the C-terminus of one subunit with a region immediately downstream of helix $\alpha 8''$ in the C-terminus of an adjoining monomer [18].

Here, we have investigated *Plasmodium falciparum* PLP synthase and report that helix $\alpha 8''$ is a prerequisite for hexamer assembly, and consequently for dodecamer formation. C-terminal deletion studies demonstrate that imine formation between R5P and K83 and subsequent conversion to the chromophoric I_{320} intermediate only requires six amino acid residues additional to helix $\alpha 8''$. However, full PLP synthetic activity then requires the native C-terminus. Hexamer/dodecamer formation is a prerequisite for covalent R5P-binding and accordingly for PLP synthase activity, however the glutaminase does not require an oligomeric Pdx1 complex for activation.

2. Materials and methods

2.1. Reagents

Antibiotics were purchased from AppliChem (Darmstadt, FRG), imidazole, 2-amino-2-(hydroxymethyl)-1,3-propanediol (Tris), NaCl, NH₄Cl, EDTA, Luria-Broth medium (LB), β -mercaptoethanol from Carl Roth (Karlsruhe, FRG), isopropyl β -D-1-thiogalactopyranoside (IPTG) was from PeqLab (Erlangen, FRG), L-glutamine, DL-G3P and R5P from Sigma–Aldrich (Taufkirchen, FRG). Restriction enzymes and DNA-polymerases were from New England Bioloabs (NEB, Schwalbach, FRG).

2.2. Molecular biology

Cloning of Pdx1 of *Plasmodium falciparum* (*Pf*Pdx1) into pET21a(+) has been described previously [5]. *Pf*Pdx1 and the C-terminally truncated versions PfPdx1 $_{\Delta 270-301}$, PfPdx1 $_{\Delta 273-301}$, PfPdx1 $_{\Delta 279-301}$ and PfPdx1 $_{\Delta 287-301}$ were generated by standard PCR and site mutagenesis using PfPdx1 as template and oligonucleotide primers as given in Supplement. All fragments were cloned via *Ndel*|*Xho*| restriction sites into pET28a(+) (Novagen, Merck, Nottingham, UK) generating N-terminally $6 \times$ His-tagged fusion proteins. The generation of additional deletion variants is described in Supplement.

2.3. Protein expression and purification

Plasmids were transformed into E. coli BL21-CodonPlus(DE3)-RIL cells (Stratagene, Amsterdam, NL) and expressed at 37 °C in LB medium containing 35 μg/ml chloramphenicol and 30 μg/ml kanamycin. The cells were induced at an OD_{600} of 0.5 with 0.1 mM IPTG. The bacteria were harvested after 3 h, washed with 150 mM NaCl and stored at -80 °C. For purification, the cell pellets were thawed and resuspended in lysis buffer (50 mM Tris-HCl pH 8.0, 300 mM NaCl, 20 mM imidazole, 10 mM β-mercaptoethanol) and disrupted by sonification. The lysate was cleared by centrifugation (30 min, 20 000×g, 4 °C) and applied to Ni-NTA agarose (QIAgen, Hilden, FRG). After washing with 40 mM imidazole the proteins were eluted with 200 mM imidazole in lysis buffer. Except for $PfPdx1_{\Delta 279-301}$, the purified variants were concentrated using Amicon centrifugal filter devices with a molecular weight cut-off of 30 kDa (Millipore Corp., Billerica, USA) and applied to a Superdex 200 10/300 GL column (GE Healthcare, Freiburg, FRG) equilibrated with assay buffer (20 mM Tris-HCl pH 8.0, 10 mM NaCl, 0.5 mM EDTA). $PfPdx1_{\Delta 279-301}$ interacted with the Superdex matrix, therefore fractions containing the variant were pooled after the Ni-NTA purification and dialysed over night against assay buffer.

2.4. Enzymatic assays

All variants were tested for PLP synthase activity as described in Refs. [5,19]. Formation of PLP was assayed using a Jasco V-550 spectrophotometer (Jasco, Groß-Umstadt, FRG) at a wavelength of 414 nm at 37 °C for 30 min. Formation of the I_{320} chromophoric intermediate was monitored at 315 nm [17]. 20 μ M purified PfPdx1 or variants and 20 μ M Pdx2 of $Plasmodium\ falciparum\ (Pf$ Pdx2) were incubated in assay buffer in the presence of 1 mM R5P, 1 mM G3P and 10 mM L-glutamine. In the absence of PfPdx2, 10 mM NH4Cl was used as nitrogen source. G3P was not added for the analysis of I_{320} -formation.

Glutaminase activity was determined as described previously [5]. Briefly, 5 μ M of PfPdx1 or variants and 5 μ M of PfPdx2 were incubated for 15 min at 30 °C with 10 mM ι -glutamine, 0.5 mM 3-acetylpyridine adenine dinucleotide (APAD) and 10 U glutamate dehydrogenase. Reduction of APAD to APADH was monitored at 363 nm.

2.5. Static light scattering

To determine the absolute molecular weight without the use of internal standards, a gel filtration setup using a Superdex 200 10/300 GL size exclusion chromatography column (GE Healthcare, Freiburg, FRG) in line with static light scattering was used. The buffer used was 20 mM Tris–HCl pH 8.0, 100 mM NaCl. For in-line detection, a Mini Dawn light scattering instrument (Wyatt Technology, Dernbach, FRG) and a refractory index detector (WGE Dr. Bures, Dallgow, FRG) were used. Data were evaluated using the AstraV software (Wyatt Technology, Dernbach, FRG).

2.6. Analytical ultracentrifugation

The oligomeric states of PfPdx1 and all deletion variants were analysed by analytical ultracentrifugation (AUC). The sedimentation velocity was determined using a Beckman Optima XL-A ultracentrifuge (Beckman Coulter, USA). Runs were performed at 20 °C, 35 000 rpm or 42 000 rpm, λ = 280 nm, with a protein concentration of \sim 65 μ M in a buffer comprised of 20 mM Tris–HCl pH 8.0 and 100 mM NaCl. Buffer density, viscosities and protein partial specific volumes were calculated with the SEDNTERP program version 1.09 (http://www.rasmb.bbri.org, [20]). For analysis of the AUC data the program SEDFIT version 11.9b [21] was used. Calculations of sedimentation coefficients from the crystal structure coordinates were performed with the software HYDROPRO [22].

2.7. Mass spectrometry

Protein samples were purified using reversed phase μ C4 micropipette tips (ZipTips, Millipore, Billerica, MA, USA) according to the manufacturers' protocol. NanoESI-MS experiments were carried out on a QTOF2 mass spectrometer (Waters, Micromass, Manchester, UK). Samples were sprayed from in-house produced gold coated spray needles. Static electrospray was established by applying a capillary voltage of 1000 V. Data acquired were analyzed by MassLynx 4.1.

3. Results

The C-terminal region of Pdx1 is responsible for intersubunit cross-talk and confers cooperativity to the enzyme [18]. The full C-terminus of Pdx1 is not resolved in prokaryotic 3D structures [9,10,23] and in these structures helix $\alpha 8''$ is the most C-terminal secondary structure element in the core of Pdx1 (Fig. 1A). However, a substantial portion of the C-terminus has been resolved with the




Fig. 1. Deletion analysis of Pdx1 of *Plasmodium falciparam*. (A) Shown is the structure of *Saccharomyces cerevisiae* Pdx1 (3FEM); two stereo views of adjacent subunits of one hexamer are presented. Large parts of the 3D structure have been omitted for clarity. The C-terminal regions of previously determined structures from Thermotoga maritima (TmPdx1, yellow, 2ISS), *Methanocaldococcus jannaschii* (MjPdx1, magenta, 2YZR) and *Bacillus subtilis* (BsPdx1, blue, 2NV2) are also shown. Pi stands for inorganic phosphate and indicates the binding site for the substrate pentose phosphate. (B) The alignment displays the relevant sequences and the secondary structure assignment. In the alignment, amino acids present in the 3D structure are given in capital and boxed. The sequence of PfPdx1 is given with a secondary structure prediction using Jpred 3 [26]. The table lists enzymatic activities and oligomeric state for the referenced PfPdx1 deletion variants. n.d.: not determined.

3D structure of the eukaryotic Pdx1 protein from *Saccharomyces cerevisiae* [24]. In the yeast structure, helix $\alpha 8''$ is followed by a

random coil region leading into helix αC [24]. Remarkably, the partly resolved random coil regions of the bacterial structures

Table 1Biochemical characterization of *Pf*Pdx1 and its C-terminal truncation variants using NH₄Cl as ammonium donor.

Protein	R5P-binding ^a	I ₃₂₀ -specific activity		PLP-specific activity		Oligomeric state ^b
		$\mathrm{nmol}\ \mathrm{min}^{-1}\ \mathrm{mg}^{-1}$	%	pmol min ⁻¹ mg ⁻¹	%	
PfPdx1	+	1.22 ± 0.04	100	695 ± 71	100	Dodecamer
PfPdx1 $_{\Delta 270-301}$	_	n.d.	0	n.d.	0	Mainly monomer
$PfPdx1_{\Delta 273-301}$	_	n.d.	0	n.d.	0	Dodecamer
PfPdx1 $_{\Delta 279-301}$	+	1.3 ± 0.4	107	351 ± 77	51	Dodecamer
$PfPdx1_{\Delta 287-301}$	+	1.9 ± 0.2	155	_c	_c	Dodecamer

Assays were performed with 20 μ M protein, 1 mM R5P, 1 mM G3P, 10 mM NH₄Cl in 20 mM Tris–HCl pH 8.0, 10 mM NaCl, 0.5 mM EDTA. The activity of PfPdx1 was set as 100 %. Experimental results are means of at least three independent measurements. n.d.: none detected.

- ^a Compare Table 4.
- ^b Compare Table 3.
- ^c Protein precipitated upon addition of G3P.

and the yeast structure superpose well, suggesting relevance of the observed conformation in this region (Fig. 1A).

Secondary structure predictions for the C-terminus of PfPdx1 confirm the positioning of helix $\alpha 8''$, however, the predicted C-terminal helix αC is shifted and extended compared to that of Saccharomyces Pdx1. Based on this analysis, we designed the following C-terminal deletion variants: $PfPdx1_{\Delta 270-301}$, truncating the protein at the last turn of helix $\alpha 8''$; PfPdx1 $_{\Delta 273-301}$, truncating the protein immediately after helix $\alpha 8''$; PfPdx1 $_{\Delta 279-301}$, truncating the protein between helices $\alpha 8''$ and αC ; and finally $PfPdx1_{\Delta 287}$ $_{301}$, truncating the protein after the resolved part of helix αC in S. cerevisiae Pdx1 but before the predicted helix αC of P. falciparum (Fig. 1B; additional variants indicated in the figure are presented in Supplement). After expression and purification, the variants were characterized with respect to their oligomeric state and their abilities to bind R5P, to form the chromophoric reaction intermediate I₃₂₀ [13,17] and to synthesise PLP [5]. Furthermore, the glutaminase activity of the Pdx1/Pdx2 complex was determined [5].

The oligomerisation behaviour of Pdx1 was altered in the shortest variant, PfPdx1 $_{\Delta 270-301}$, as determined by analytical ultracentrifugation (Tables 1 and 3, Fig. 2A). This behaviour was independently confirmed by size exclusion chromatography coupled with static light scattering (Fig. 2B). The dominant species was the monomer with a sedimentation coefficient of 3.0 ± 0.1 S making up roughly two thirds (68%) of the total protein. Species with sedimentation coefficients of 4.8 ± 0.5 S and 6.9 ± 1.1 S corresponding roughly to dimeric and tetrameric forms were also present. The

analytical ultracentrifugation data displayed broad peaks for the oligomeric species suggesting a fast equilibrium between several states (Fig. 2A). Interestingly, PfPdx1 $_{\Delta 270-301}$ was able to fully activate the glutaminase Pdx2, suggesting that the monomeric species retained this propensity (Table 2). This also suggests that this truncation variant possesses an intact Pdx1–Pdx2 interface.

PfPdx1 $_{\Delta 270-301}$ proved to be catalytically inactive for I $_{320}$ and PLP formation either alone or in complex with PfPdx2 (Tables 1 and 2). This prompted us to investigate whether this variant is able to bind R5P. PfPdx1 $_{\Delta 270-301}$ was incubated with R5P and the molecular mass was determined by ESI-MS. When wild-type PfPdx1 is incubated with R5P, the determined molecular mass in ESI-MS changes by 212 Da, reflecting the formation of a covalent Schiff base between R5P and the catalytic lysine 83 (Table 4) [10,14,17,18]. However, the molecular mass of PfPdx1 $_{\Delta 270-301}$ remained unaltered upon incubation with R5P, indicating that this variant is incapable of forming the covalent imine intermediate with its pentose substrate (Tables 1 and 4).

In $PfPdx1_{\Delta 270-301}$, PfPdx1 is truncated within helix $\alpha 8''$ which is at the oligomerisation interface. Hence the deletion mutant $PfPdx1_{\Delta 273-301}$ was examined in which the truncation occurs just after helix $\alpha 8''$ and this protein was found to form dodecamers (Tables 1 and 3). The three additional amino acids in $PfPdx1_{\Delta 273-301}$ are a conserved serine that makes a hydrophilic contact with a backbone atom of the preceding helical turn followed by two solvent exposed and variable residues. A mutant in which the serine was replaced by an alanine ($PfPdx1_{5270A\Delta 273-301}$ variant; see




Fig. 2. Oligomeric nature of PfPdx1 $_{\Delta 270-301}$ analyzed in solution (A) the main peak observed in sedimentation velocity analytical ultracentrifugation is fitted to a sedimentation coefficient s = 3.0 S, which corresponds to a monomeric species with a molecular mass of 29 kDa. The sedimentation coefficients of the minor peaks were at 4.8 S and 6.9 S, respectively. These represent higher oligomeric forms that appear to be in a rapid equilibrium, as suggested by the shallow shape of the peaks. (B) For absolute mass determination without use of internal standards, size exclusion chromatography in line with RI-detection and static light scattering was performed. The fitted molecular mass of the observed peak was 35 kDa $\pm 2\%$.

Table 2Biochemical characterization of *Pf*Pdx1 and its C-terminal truncation variants in presence of *Pf*Pdx2.

Protein + PfPdx2	I ₃₂₀ -specific activity		PLP-specific activity		Glutaminase-specific activity	
	nmol min ⁻¹ mg ⁻¹	%	pmol min ⁻¹ mg ⁻¹	%	nmol min ⁻¹ mg ⁻¹	%
PfPdx1	2.76 ± 0.2	100	779 ± 130	100	193.90 ± 14	100
$PfPdx1_{\Delta 270-301}$	n.d	0	n.d.	0	190.60 ± 3	99
PfPdx1 $_{\Delta 273-301}$	n.d	0	n.d.	0	202.77 ± 16	105
$PfPdx1_{\Delta 279-301}$	4.62 ± 0.4	167	250 ± 32	32	271.62 ± 8	140
PfPdx1 _{∆287-301}	2.25 ± 0.1	83	_a	_a	182.76 ± 9	94

Assays were performed with 20 µM protein, 1 mM R5P, 1 mM G3P, 10 mM L-glutamine in 20 mM Tris–HCl pH 8.0, 10 mM NaCl, 0.5 mM EDTA. The activity of PfPdx1/PfPdx2 was set as 100%. Experimental results are means of at least three independent measurements. n.d. – none detected.

Table 3Analysis of Pdx1 and the C-terminal truncation variants by analytical ultracentrifugation (velocity sedimentation).

Protein	$s_{\text{exp}}(S)^{a}$	M _{exp} (kDa) ^b	M _{cal} (kDa) ^c
PfPdx1	14.0	363	420
$PfPdx1_{\Delta 270-301}^{d}$	Peak 1: 3.0 ± 0.1	29 ± 3	31
	Peak 2: 4.8 ± 0.5	60 ± 12	-
	Peak 3: 6.9 ± 1.1	110 ± 26	-
$PfPdx1_{\Delta 273-301}$	12.9	324	380
PfPdx1 $_{\Delta 279-301}$	13.0	330	387
PfPdx1 $_{\Delta 287-301}$	13.8	354	400

^a The c(S) distribution of sedimentation coefficients was determined with SEDFIT [21] and corrected to standard conditions (20 °C, H₂O). Calculated s values using HYDROPRO and 3.1 Å bead size [22] are 2.7 S for the monomeric and 15.4 S for the dodecameric species.

Table 4Molecular mass of *Pf*Pdx1 and the C-terminal truncation variants in the absence or presence of ribose 5-phosphate as determined by ESI-MS.

Protein	-R5P (Da)	+R5P (Da)
PfPdx1	35320.7	35532.6
PfPdx1 _{\(\text{\Delta}270-301\)}	31506.8	31506.8
PfPdx1 _{\(\text{\Delta}273-301\)}	31722.6	31722.6

Supplement Tables S1 and S3) was dodecameric, suggesting that the length of the helical segment is crucial for the integrity of the oligomerisation interface.

The PfPdx1 $_{\Delta 273-301}$ variant was unable to produce the chromophoric reaction intermediate I $_{320}$ and, consequently, has no PLP synthetic activity (Tables 1 and 2). Similarly, the BsPdx1 $_{\Delta 273-294}$ variant, roughly equivalent to PfPdx1 $_{\Delta 273-301}$ but containing two additional amino acids at the C-terminus, was severely impaired in the formation of the chromophore (0.5% of wild-type activity) and displayed no detectable PLP synthase activity [18]. Using ESI-MS, we could show that PfPdx1 $_{\Delta 273-301}$ was unable to covalently bind the pentose substrate (Tables 1 and 4). However, PfPdx1 $_{\Delta 273-301}$ was able to fully activate PfPdx2 similarly to the wild-type protein (Table 2).

Inclusion of additional six amino acid residues in PfPdx1 $_{\Delta 279-301}$ elicits chromophore-specific activity. This variant is dodecameric in nature (Tables 1 and 3) and shows chromophore-specific activity similar to the wild-type protein, whereas PLP-specific activity was halved (Table 1). The six additional amino acids, of which glycine

274 and methionine 277 are conserved among Pdx1 orthologs, are thus required for imine formation with R5P and the formation of the chromophoric intermediate. I₃₂₀-specific activity increased above that of wild-type in the Pdx2-dependent assay (167% versus 100%; Table 2), while PLP-specific activity was further reduced (32%; Table 2). Thus, Pdx2 in its glutamine bound form has an influence on chromophore formation, exerting an allosteric effect [18], even when only the truncated form is considered.

PfPdx1_{A287-301} contains the segment equivalent to the resolved part of helix αC of the S. cerivisiae Pdx1. This variant forms dodecamers and exhibits chromophore-specific activity (Tables 1-3). Unlike $PfPdx1_{A279-301}$, the I_{320} -specific activity of $PfPdx1_{A287-301}$ was greater than that of wild-type in the absence of Pdx2 (155% versus 100%), but slightly decreased in the presence of Pdx2 (83% versus 100%) (Tables 1 and 2). Further, no PLP-specific activity could be determined for $PfPdx1_{\Delta 287-301}$, since addition of G3P resulted in an instantaneous precipitation of the protein. Indeed, we have tested two further deletion variants and observed the same behaviour and similar stability problems (PfPdx1_{\Delta293-301} and $PfPdx1_{\Delta 295-301}$, see Supplement). The very C-terminus with the predicted C-terminal helix likely is an independent functional domain allowing Pdx1 to accommodate conformational changes that occur upon or as a consequence of G3P binding. If the integrity of this domain is disturbed, G3P integration into the forming PLP molecule is impaired. Thus, only the native C-terminus ensures optimal PLP biosynthesis.

4. Discussion

The C-terminus of Pdx1, which has evaded structural determination, is essential for catalytic activity of the protein [18]. In the current study, we performed a deletion analysis and assigned specific functions to defined regions of the C-terminus. Variants were characterized with respect to (i) their ability to form the hexamer/dodecamer state of wild-type protein, (ii) their enzymatic properties, i.e., substrate binding, I₃₂₀-formation and PLP synthesis, and (iii) their ability to activate Pdx2, the glutaminase partner.

The $PfPdx1_{\Delta 270-301}$ variant with truncated helix $\alpha 8''$ was the only variant that had defective oligomerization behaviour. This protein adopted several oligomeric states with the monomer being the predominant species (Fig. 2). The other deletion variants tested here showed dodecameric organization. Thus, integrity of helix $\alpha 8''$ is essential to stabilize the oligomer, as can be proposed on the basis of crystallographic analyses [9,10,23]. Exchanges of conserved amino acid residues in the loop preceding helix $\alpha 3$, which likewise are at the interface between protamers, also affected the oligomerisation behaviour of Pdx1 [25].

Interestingly, the $PfPdx1_{\Delta 270-301}$ variant was able to fully activate the glutaminase PfPdx2 (Table 2). It is possible that this activity is due to presence of transient hexamers. However, glutaminase activation is identical to native PfPdx1/PfPdx2 complexes and on

^a - Protein precipitated on addition of G3P.

 $^{^{\}rm b}$ Molecular mass derived from molar mass distributions c(M) calculated by SEDFIT. For all dodecameric variants the frictional ratio was fixed to 1.25 (average of all experiments).

^c Molecular mass calculated from the amino acid composition.

 $^{^{}m d}$ Three different species were detected. The monomeric form fitted to 3.0 ± 0.1 S and comprised about two thirds of the total protein. The standard deviation is given on the basis of three independent experiments. Higher oligomeric forms are probably in fast equilibrium giving rise to larger errors as discussed in the text (no theoretical s and M values calculated).

this basis we propose that a Pdx1 monomer is able to interact with and activate the Pdx2 glutaminase. Importantly, this is in contrast to the earlier finding that the monomeric Pdx1 variant with exchanges of conserved amino acid residues in the loop preceding helix α 3 was unable to activate the glutaminase partner Pdx2 [25].

Neither $PfPdx1_{\Delta 270-301}$ nor $PfPdx1_{\Delta 273-301}$ was capable of covalently binding the substrate R5P. This suggests that a Pdx1 dodecamer is required for binding of the pentose substrate and that the protein must extend over the "minimal" core as represented by the $PfPdx1_{\Delta 273-301}$ variant. The $PfPdx1_{\Delta 279-301}$ variant then binds R5P and also forms the I_{320} intermediate and PLP. Full PLP synthase activity, however, requires the native C-terminus from amino acid 279 onward. Thus, within the C-terminal segment investigated here, R5P-binding and I_{320} -formation are assigned to amino acids 273–278.

The C-terminal region from residue 273 on is in close proximity to helix $\alpha 8'$ and the loop between $\beta 6$ and $\alpha 6$ of the $(\beta \alpha)_8$ -barrel (Fig. 1A) both of which have been implied in phosphate binding of the substrate R5P [10]. It is likely that the C-terminal segment helps organising the whole structural region and in consequence substrate binding, because of two reasons: the observed close proximity and the observation that the C-terminal segment superposes well in all structures, where it was resolved (Fig. 1A).

The $PfPdx1_{\Lambda 279-301}$ variant is competent for PLP formation, however, at a reduced level (Tables 1 and 2). It is therefore quite likely that the C-terminus beyond Cys278 including helix αC is an independent domain required for optimal PLP production. Interestingly, helix αC is in close proximity to helix $\alpha 2'$ of a neighbouring subunit [24]. This likely explains the observed cooperativity in the oligomeric enzyme [18]. Raschle et al. proposed that the C-terminus may act as a lid to close the active site, and they proposed this function is dependent on presence of R5P [18]. The structural and mutational analysis presented here now suggests that the first part of the C-terminus acts in cis, organising phosphate binding of the pentose substrate, while, by analogy to the S. cerevisiae structure, the very C-terminus from helix α C onward acts in trans, organising the $\alpha 2'$ region, likewise implied in pentose binding. The truncation variant $PfPdx1_{\Delta 279-301}$ cannot interact with a neighbouring subunit in the proposed way and consequently lacks full PLP synthase activity. In contrast, the PfPdx1_{A287-301} variant would be able to interact in trans with the $\alpha 2'$ region, but because it precipitated upon addition of G3P - as do the variants, which were truncated C-terminally of PfPdx1_{A287-301} - formation of PLP could not be determined making it impossible to further analyze this region. We conclude that the region C-terminal to helix αC further enhances PLP formation, presumably by mediating G3P binding and/or steps subsequent to G3P incorporation. Together, the data argue for an important structural role of the C-terminus in catalysis, which explains the rather limited conservation in this region and probably the lack of consensus catalytic residues.

Acknowledgement

This work was supported in parts by the European Commission (VITBIOMAL-012158), the DFG (TE368) and funding from the University Hospital Heidelberg. We would like to thank Thorsten Brietz for his administrative support.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.febslet.2010.09.013.

References

- Snow, R.W., Guerra, C.A., Noor, A.M., Myint, H.Y. and Hay, S.I. (2005) The global distribution of clinical episodes of *Plasmodium falciparum* malaria. Nature 434, 214–217.
- [2] Guerin, P.J., Bates, S.J. and Sibley, C.H. (2009) Global resistance surveillance: ensuring antimalarial efficacy in the future. Curr. Opin. Infect. Dis. 22, 593–600.
- [3] Muller, I.B., Hyde, J.E. and Wrenger, C. (2009) Vitamin B metabolism in *Plasmodium falcingrum* as a source of drug targets. Trends Parasitol. 26. 35–43.
- [4] Muller, S. and Kappes, B. (2007) Vitamin and cofactor biosynthesis pathways in *Plasmodium* and other apicomplexan parasites. Trends Parasitol. 23, 112– 121.
- [5] Gengenbacher, M. et al. (2006) Vitamin B6 biosynthesis by the malaria parasite *Plasmodium falciparum*: biochemical and structural insights. J. Biol. Chem. 281, 3633–3641.
- [6] Wrenger, C., Eschbach, M.L., Muller, I.B., Warnecke, D. and Walter, R.D. (2005) Analysis of the vitamin B6 biosynthesis pathway in the human malaria parasite *Plasmodium falciparum*. J. Biol. Chem. 280, 5242–5248.
- [7] Fitzpatrick, T.B., Amrhein, N., Kappes, B., Macheroux, P., Tews, I. and Raschle, T. (2007) Two independent routes of *de novo* vitamin B6 biosynthesis: not that different after all. Biochem. J. 407, 1–13.
- [8] Mozzarelli, A. and Bettati, S. (2006) Exploring the pyridoxal 5'-phosphatedependent enzymes. Chem. Rec. 6, 275–287.
- [9] Strohmeier, M., Raschle, T., Mazurkiewicz, J., Rippe, K., Sinning, I., Fitzpatrick, T.B. and Tews, I. (2006) Structure of a bacterial pyridoxal 5'-phosphate synthase complex. Proc. Natl. Acad. Sci. USA 103, 19284–19289.
- [10] Zein, F., Zhang, Y., Kang, Y.N., Burns, K., Begley, T.P. and Ealick, S.E. (2006) Structural insights into the mechanism of the PLP synthase holoenzyme from *Thermotoga maritima*. Biochemistry 45, 14609–14620.
- [11] Tazuya, K., Adachi, Y., Masuda, K., Yamada, K. and Kumaoka, H. (1995) Origin of the nitrogen atom of pyridoxine in *Saccharomyces cerevisiae*. Biochim. Biophys. Acta 1244, 113–116.
- [12] Zalkin, H. and Smith, J.L. (1998) Enzymes utilizing glutamine as an amide donor. Adv. Enzymol. Relat. Areas Mol. Biol. 72, 87–144.
- [13] Hanes, J.W., Keresztes, I. and Begley, T.P. (2008) ¹³C NMR snapshots of the complex reaction coordinate of pyridoxal phosphate synthase. Nat. Chem. Biol. 4, 425–430.
- [14] Burns, K.E., Xiang, Y., Kinsland, C.L., McLafferty, F.W. and Begley, T.P. (2005) Reconstitution and biochemical characterization of a new pyridoxal-5'phosphate biosynthetic pathway. J. Am. Chem. Soc. 127, 3682–3683.
- [15] Flicker, K., Neuwirth, M., Strohmeier, M., Kappes, B., Tews, I. and Macheroux, P. (2007) Structural and thermodynamic insights into the assembly of the heteromeric pyridoxal phosphate synthase from *Plasmodium falciparum*. J. Mol. Biol. 374, 732–748.
- [16] Neuwirth, M., Flicker, K., Strohmeier, M., Tews, I. and Macheroux, P. (2007) Thermodynamic characterization of the protein-protein interaction in the heteromeric *Bacillus subtilis* pyridoxal phosphate synthase. Biochemistry 46, 5131–5139.
- [17] Raschle, T., Arigoni, D., Brunisholz, R., Rechsteiner, H., Amrhein, N. and Fitzpatrick, T.B. (2007) Reaction mechanism of pyridoxal 5'-phosphate synthase. Detection of an enzyme-bound chromophoric intermediate. J. Biol. Chem. 282, 6098–6105.
- [18] Raschle, T., Speziga, D., Kress, W., Moccand, C., Gehrig, P., Amrhein, N., Weber-Ban, E. and Fitzpatrick, T.B. (2009) Intersubunit cross-talk in pyridoxal 5'-phosphate synthase, coordinated by the C terminus of the synthase subunit. J. Biol. Chem. 284, 7706–7718.
- [19] Raschle, T., Amrhein, N. and Fitzpatrick, T.B. (2005) On the two components of pyridoxal 5'-phosphate synthase from *Bacillus subtilis*. J. Biol. Chem. 280, 32291–32300.
- [20] Laue, T.M., Shah, B.D., Ridgeway, T.M. and Pelletier, S.L. (1992) Computer-Aided Interpretation of Analytical Sedimentation Data for Proteins in: Analytical Ultracentrifugation in Biochemistry and Polymer Science (Harding, S.E., Rowe, A.J. and Horton, J.C., Eds.), pp. 90–125, The Royal Society of Chemistry, Cambridge, UK.
- [21] Dam, J. and Schuck, P. (2004) Calculating sedimentation coefficient distributions by direct modeling of sedimentation velocity concentration profiles. Methods Enzymol. 384, 185–212.
- [22] Garcia De La Torre, J., Huertas, M.L. and Carrasco, B. (2000) Calculation of hydrodynamic properties of globular proteins from their atomic-level structure. Biophys. J. 78, 719–730.
- [23] Zhu, J., Burgner, J.W., Harms, E., Belitsky, B.R. and Smith, J.L. (2005) A new arrangement of (beta/alpha)8 barrels in the synthase subunit of PLP synthase. J. Biol. Chem. 280, 27914–27923.
- [24] Neuwirth, M. et al. (2009) X-ray crystal structure of *Saccharomyces cerevisiae* Pdx1 provides insights into the oligomeric nature of PLP synthases. FEBS Lett. 583, 2179–2186.
- [25] Muller, I.B., Knockel, J., Groves, M.R., Jordanova, R., Ealick, S.E., Walter, R.D. and Wrenger, C. (2008) The assembly of the plasmodial PLP synthase complex follows a defined course. PLoS One 3, e1815.
- [26] Cole, C., Barber, J.D. and Barton, G.J. (2008) The Jpred 3 secondary structure prediction server. Nucleic Acids Res. 36, W197–W201.